Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non–Small Cell Lung Cancer Patients

Yang, Zhe; Yang, Nong; Ou, Qiuxiang; Xiang, Yi; Jiang, Tao; Wu, Xue; Bao, Hua; Tong, Xiaoling; Wang, Xiaonan; Shao, Yang; Liu, Yunpeng; Wang, Yan; Zhou, Caicun

doi:10.1158/1078-0432.ccr-17-2310

Public

Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non–Small Cell Lung Cancer Patients

Published in Clinical Cancer Research • Mar 5, 2018

Authors:

Zhe Yang

Nong Yang

Qiuxiang Ou

Abstract

Abstract Purpose: The third-generation EGFR tyrosine kinase inhibitor osimertinib is approved to treat patients with EGFR T790M-positive non–small cell lung cancer (NSCLC) who have developed resistance to earlier-generation drugs. Acquired EGFR C797S mutation has been reported to mediate osimertinib...

Subject

Osimertinib

T790M

Gefitinib

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!